WebbPatent US11020454B2 - Fusion polypeptides and methods of use (US 11,020,454 B2); Owner: Prosit Sole Biotechnology (Beijing) Co. Ltd; Filed: 07/15/2016; Est. priority date: 07/15/2015; Status: Active Grant; Abstract: Provided are fusion polypeptides comprising fragments from a first and a second FGF family member, nucleic acids encoding the … WebbThis page provides information about law firm Wilson Sonsini Goodrich & Rosati: Clients of Wilson Sonsini Goodrich & Rosati along with the number of issued patents in the past …
Wilson Sonsini Goodrich & Rosati - Patent Bots
Webb28 feb. 2024 · Beijing-based start-up Prosit Sole Biotechnology is developing a treatment for norovirus gastroenteritis in immunocompromised patients, a market it estimates could be worth $500m per year in the ... Webb27 maj 2024 · 德益阳光生物技术(Prosit Sole Biotechnology)正在开发的PSP001用于治疗造血和实体器官移植患者的慢性诺如病毒肠炎。 “免疫功能低下人群的慢性诺如病毒肠炎,是一项迫切的待解决的医疗需求。 ”德益阳光生物技术公司首席执行官刘宏宇博士说:“目前还没有已批准的治疗这种在特殊人群中高致死率疾病的药物,与此同时,我们也在积 … cpp drop in advising
巨細胞病毒(HHV-5)感染疾病:開發中產品分析 - 日商環球訊息有限 …
WebbAktuelle Presseaussendungen zum Thema "Interferon" von St. Anna Kinderkrebsforschung und anderen Webb17 nov. 2016 · Information on valuation, funding, cap tables, investors, and executives for Prosit Sole. Use the PitchBook Platform to explore the full profile. Information on ... The … Webb( 71 ) Applicant : Prosit Sole Biotechnology ( Beijing ) Co. Ltd , Beijing ( CN ) ( 72 ) Inventors : Hongyu Liu , Beijing ( CN ) ; Mingzhi Zhao , Beijing ( CN ) ; Hetong Sun , … cppd osteoarthropathy